Orthopaedics — Reclassification to: cost of sales
Stryker Orthopaedics — Reclassification to: cost of sales increased by 3.5% to $620.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 10.5%, from $561.00M to $620.00M. Over 2 years (FY 2022 to FY 2024), Orthopaedics — Reclassification to: cost of sales shows an upward trend with a 11.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase suggests a shift in how the company accounts for production-related costs, potentially impacting reported gross margins.
Detailed definition
This represents specific costs previously categorized elsewhere that have been reclassified into the cost of goods sold...
Peer comparison
Similar to cost reclassifications or accounting adjustments found in the segment reporting of other medical device manufacturers.
syk_segment_orthopaedics_reclassification_to_cost_of_salesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $480.00M | $480.00M | $480.00M | $480.00M | $563.50M | $563.50M | $563.50M | $563.50M | $591.00M | $576.00M | $561.00M | $672.00M | $629.00M | $599.00M | $620.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +17.4% | +0.0% | +0.0% | +0.0% | +4.9% | -2.5% | -2.6% | +19.8% | -6.4% | -4.8% | +3.5% |
| YoY Change | — | — | — | — | +17.4% | +17.4% | +17.4% | +17.4% | +4.9% | +2.2% | -0.4% | +19.3% | +6.4% | +4.0% | +10.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Stryker's orthopaedics — reclassification to: cost of sales?
- Stryker (SYK) reported orthopaedics — reclassification to: cost of sales of $620.00M in Q3 2025.
- How has Stryker's orthopaedics — reclassification to: cost of sales changed year-over-year?
- Stryker's orthopaedics — reclassification to: cost of sales increased by 10.5% year-over-year, from $561.00M to $620.00M.
- What is the long-term trend for Stryker's orthopaedics — reclassification to: cost of sales?
- Over 2 years (2022 to 2024), Stryker's orthopaedics — reclassification to: cost of sales has grown at a 11.8% compound annual growth rate (CAGR), from $1.92B to $2.40B.
- What does orthopaedics — reclassification to: cost of sales mean?
- Adjustments that move expenses into the direct cost of producing orthopedic goods.